Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs.

No abstract is available for this paper.

• Publication year

  1983

• Venue

  Journal of Pharmacobio-Dynamics

• Publication date

  1983-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1248/BPB1978.6.866PMID 6668545
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alkyl Ether Analogs of Phosphatidylcholine Are Orally Active in Hypertensive Rabbits

  1981cited by this paper
• Identification of platelet activating factor isolated from rabbit basophils as acetyl glyceryl ether phosphorylcholine.

  1980cited by this paper
• Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine, a mediator of IgE anaphylaxis in the rabbit.

  1980cited by this paper
• Antihypertensive activity of an alkyl ether analog of phosphatidylcholine.

  1979cited by this paper
• Antihypertensive Polar Renomedullary Lipid, A Semisynthetic Vasodilator

  1979cited by this paper
• Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species

  1978cited by this paper
• RELEASE OF VASOACTIVE AMINES FROM RABBIT PLATELETS INDUCED BY SENSITIZED MONONUCLEAR LEUKOCYTES AND ANTIGEN

  1970cited by this paper

• Investigation of the involvement of platelet-activating factor in the control of hypertension by aerobic training. A randomized controlled trial

  2023cites this paper
• Interrelationships among platelet‐activating factor and lipoprotein‐associated phospholipase A2 activity and traditional cardiovascular risk factors

  2022cites this paper
• Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis.

  2006cites this paper
• Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis

  2004cites this paper
• Endothelium-dependent relaxant action of platelet activating factor in the rat mesenteric artery

  2004cites this paper
• Platelet function and coronary artery disease

  2001cites this paper
• Possible involvement of endothelium‐derived hyperpolarizing factor (EDHF) in the depressor responses to platelet activating factor (PAF) in rats

  2000cites this paper
• PAF and Antigen-Induced Bronchial Hyperreactivity in Guinea Pigs

  1996cites this paper
• Hypotensive reactions: a previously uncharacterized complication of platelet transfusion?

  1996cites this paper
• Biological and pharmacological effects of pinusolide, a novel platelet activating factor antagonist.

  1995cites this paper
• The antagonistic effects of khellactones on platelet-activating factor, histamine, and leukotriene D4.

  1995cites this paper
• Effect of the platelet activating factor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride on endotoxin-induced hypotension and hematological parameters in rats.

  1994cites this paper
• TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock

  1994cites this paper
• Studies on the hypotensive mechanisms of NZ-105, a new dihydropyridine derivative, in rats and rabbits.

  1993cites this paper
• Hypotensive effect of bopindolol in pithed rats.

  1993cites this paper
• Existence of PAF receptors in human platelets and human lung tissue but not in the human myocardium.

  1992cites this paper
• Cardiovascular effects of Acanthaster planci venom in the rat: possible involvement of PAF in its hypotensive effect.

  1992cites this paper
• Involvement of nitric oxide pathway in the PAF‐induced relaxation of rat thoracic aorta

  1992cites this paper
• Putative mechanism of hypotensive action of platelet-activating factor in dogs.

  1992cites this paper
• Mechanisms of the cardioprotective actions of WEB-2170, bepafant, a platelet activating factor antagonist, in myocardial ischemia and reperfusion.

  1992cites this paper
• Mode of action of the triazolobenzodiazepines in the treatment of panic attacks: a hypothesis.

  1992cites this paper
• Endothelin-1 enhances vascular permeability in conscious rats: role of thromboxane A2.

  1992cites this paper
• Effects of Platelet Activating Factor on Contractions and Ca Influx Induced by Noradrenaline and Potassium in Rat Rubbed and Intact Aorta. Comparison with Its Hypotensive Effect in Anaesthetized Normotensive Rats

  1992cites this paper
• Action of the racemate and the isomers of the platelet-activating factor antagonist bepafant (WEB 2170) after oral administration to guinea-pigs and rats

  1991cites this paper
• Cardiopulmonary and intravascular alterations during the sustained infusion of PAF.

  1991cites this paper
• Interactions between platelet-activating factor and prostanoids during mesenteric ischemia-reperfusion-induced shock in the anesthetized dog.

  1991cites this paper
• Attenuation of depressor response induced by platelet activating factor and acetylcholine in streptozotocin-induced diabetic rats.

  1991cites this paper
• Effect of platelet-activating factor (PAF) and synthetic analogues on fibrinolysis in rats

  1990cites this paper
• Preclinical and clinical pharmacology of platelet‐activating factor receptor antagonists

  1990cites this paper
• PROLONGED SURVIVAL OF RENAL TRANSPLANTS IN NONIMMUNIZED AND HYPERIMMUNIZED RATS RECEIVING A PLATELET‐ACTIVATING FACTOR ANTAGONIST

  1990cites this paper
• Immunopharmacology Reviews

  1990cites this paper
• The Pharmacology of microbial Modulation in the Induction and Expression of Immune Reactivities

  1990cites this paper
• A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine.

  1990cites this paper
• Induction of tissue injury and altered cardiovascular performance by platelet-activating factor: relevance to multiple systems organ failure.

  1989cites this paper
• Platelet-activating factor: lack of direct action on guinea pig myocardium and possible transmitter release from cardiac sympathetic nerve endings at high concentrations.

  1989cites this paper
• Endothelium‐dependent vasodilator effects of platelet activating factor on rat resistance vessels

  1989cites this paper
• Pharmacological Modulation of Platelet Activating Factor (PAF)‐induced Bronchoconstriction and Hypertension in Anaesthetized Guinea‐pigs

  1988cites this paper
• High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.

  1988cites this paper
• [Effects of platelet activating factor on the bronchial musculature and vasculature in dogs].

  1988cites this paper
• Platelet-activating factor-induced increases in glucose kinetics.

  1988cites this paper
• Platelet-activating factor antagonists.

  1987cites this paper
• Direct effects of platelet activating factor (PAF) on cardiac function in isolated guinea pig heart

  1987cites this paper
• In Vitro and In Vivo Pharmacological Profiles of the PAF Receptor Antagonist SRI 63-675

  1987cites this paper
• Potentiation by bovine serum albumin (BSA) of endothelium-dependent vasodilator response to acetyl glyceryl ether phosphorylcholine (AGEPC).

  1987cites this paper
• Biological properties of the antagonist SRI 63-441 in the PAF and endotoxin models of hypotension in the rat and dog.

  1987cites this paper
• Synthesis and biological activity of fluorine-modified platelet activating factors.

  1987cites this paper
• Evidence for distinct systemic extravasation effects of platelet activating factor, leukotrienes B4, C4, D4 and histamine in the guinea pig.

  1986cites this paper
• Inhibition of PAF-lnduced Systemic Responses in the Rat, Guinea Pig, Dog and Primate by the Receptor Antagonist SRI 63-441

  1986cites this paper
• Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist.

  1986cites this paper
• Platelet activating factor and inflammation in atherogenesis: Targets for drug development

  1986cites this paper
• PAF-acether-induced release of tissue-type plasminogen activator from vessel walls.

  1985cites this paper
• Evidence for a Direct Effect on Vascular Permeability of Platelet-Activating Factor Induced Hemoconcentration in the Guinea Pig

  1985cites this paper
• An enantioselective synthesis of platelet-activating factors, their enantiomers, and their analogues from D- and L-tartaric acids.

  1985cites this paper
• Platelet activating factor analogues: lack of correlation between their activities to produce hypotension and endothelium-mediated vasodilation.

  1985cites this paper
• Chapter 20. Platelet-Activating Factor: Multifaceted Biochemical and Physiological Mediator

  1985cites this paper
• Hypotensive actions of some analogues of platelet-activating factor (PAF) with higher potencies than natural PAF.

  1984cites this paper
• Possible role of endothelium in the vasodilator response of rat thoracic aorta to platelet activating factor (PAF).

  1984cites this paper